Sattvam Enterprise AI is building the world's first vertically integrated, specialty-native AI platform for healthcare — starting with obstetrics and gynecology. We are not building another horizontal scribe. We are building the operating system for how specialty medicine will be practiced in the AI era.
Multiple converging TAMs with explosive growth trajectories
Defensible technology built through deep domain engineering, not generic API wrappers
Poka-yoke Drug Correction Engine — Multi-layered error prevention system combining Levenshtein distance, Soundex phonetic matching, regex pattern libraries, and phonetic maps. Contains 2,200+ drug name variations, 1,800+ compiled phonetic regexes, and 467 quick-fix patterns for Indian brand drugs.
21-Agent Orchestration Architecture — Proprietary multi-agent system where each agent manages a specific clinical workflow (intake, vitals, consulting, ANC, surgery, discharge, billing) with cross-agent context sharing and clinical state management.
Indian OBGYN Drug Database — Curated formulary of 340+ Indian pharmaceutical brand names with generic compositions, phonetic mappings for Hindi/Gujarati/regional accent mishearings, and dosage-form classification. No publicly available equivalent exists.
Medical Speech Processing Pipeline — End-to-end voice processing stack tuned for Indian English with OBGYN terminology: fast pre-correction, AI extraction, post-correction safety nets, and hallucination prevention filters.
Replacement Cost Approach — The Poka-yoke engine alone represents 12+ months of iterative clinical testing and refinement. The drug database, phonetic maps, and agent architecture collectively represent 2+ years of engineering effort with continuous hospital-feedback optimization loops.
Market Comparables — Eka Care (closest India-native comparable) raised $19.5M at a reported three-digit-million post-money valuation with a horizontal approach. Our vertical-first strategy in a $267B FemTech market provides differentiated IP positioning.
Growth Trajectory of IP Value — Every consultation processed adds to our drug correction accuracy. Every doctor interaction refines our phonetic models. The IP appreciates with usage — a compounding data moat that horizontal players cannot replicate without vertical focus.
Future IP Expansion — SattvamIPD (inpatient module) in development. Each new specialty vertical (Pediatrics, Cardiology, Orthopedics) reuses 60-70% of core IP while adding specialty-specific drug databases, agent configurations, and clinical workflows.
Four compounding moats that deepen with every patient interaction
2,200+ drug name variations mapped to correct names. Built from real clinical mishearings — not synthetic data. Every correction logged, analyzed, and fed back into the engine.
21 agents covering the full OBGYN patient journey. Not a scribe — an operating system. Each agent encodes clinical logic (ANC intervals, trimester protocols, surgical checklists) that took years to validate.
340+ Indian pharmaceutical brands with prefix mappings, generic compositions, and accent-aware phonetics. Horizontal platforms use US drug databases. We use what Indian doctors actually prescribe.
Voice input → drug correction → prescription → WhatsApp delivery → discharge summary. Every step is connected. Competitors stitch together third-party APIs. We own the full stack.
Proven model in OBGYN, expanding to adjacent specialties
Multiple revenue streams with high retention and expansion potential
Market size figures cited on this page are sourced from third-party research firms (Grand View Research, Research and Markets, SNS Insider, MarketsandMarkets) and represent their independent projections. Different firms use different methodologies and category definitions — figures should be treated as directional indicators, not guaranteed outcomes. Sattvam Enterprise AI's internal market estimates and IP valuation frameworks are forward-looking and subject to market conditions, execution risk, and competitive dynamics. This page does not constitute an offer of securities or investment advice. Prospective investors should conduct independent due diligence.
We welcome conversations with investors, strategic partners, and healthcare organizations interested in the future of specialty AI.